Previous close | 0.8800 |
Open | 0.9000 |
Bid | 0.8568 x 100 |
Ask | 0.9223 x 100 |
Day's range | 0.8700 - 0.9049 |
52-week range | 0.8500 - 6.0000 |
Volume | |
Avg. volume | 83,696 |
Market cap | 19.052M |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.6200 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 5.00 |
ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 MillionBERKELEY, Calif. and MAINZ, Germany, April 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today financial results for the fiscal year ended December 31, 2023. “This past fiscal year represented an important period of progress for the C
BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, will be organizing the HALLO DOC! event, informing about colorectal cancer, cutting-edge research, new treatment modalities, and holistic therapeutic approaches. This event will take place on March 20, 2024, in Berlin, Germany, aligning with the Colorectal Cancer Awareness Month.
BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024. Designed for pharmacists, physicians, and healthcare professionals, this online training session ai